Search

Displaying results 1831 - 1840 of 5758 in total
  1. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH) . Mecasermin rinfabate is similar to DB01277 in tha...

  2. Drug

    Oxytocin

    go.drugbank.com/drugs/DB00107
    ApprovedInvestigationalVet approved

    [A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work.

    Products: Oxyla 10 IU/mL Injection, SYNTOCINON INJECTION 10 iu/ml
  3. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  4. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld.

  5. Drug

    Amorolfine

    go.drugbank.com/drugs/DB09056
    ApprovedWithdrawn

    However, full experimental details of these trials were not available and since they were first reported in 1992 there have been no subsequent trials.

  6. Drug

    Drospirenone

    go.drugbank.com/drugs/DB01395
    ApprovedInvestigational

    Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    The cell culture process used in the manufacture of Thrombin Alfa employs no additives of human or animal origin.

  8. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Phenolphthalein

    go.drugbank.com/drugs/DB04824
    ApprovedWithdrawn

    Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.

    Mixtures: Herbalax Forte No 70 Tab
  10. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates